<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 23 Sep 2026 20:15:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[Virax Biolabs Group]]></title>
      <link>https://www.redchip.com/webinar/VRAX/86449600416</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/VRAX/86449600416</guid>
      <pubDate>Tue, 25 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Clinch Resources]]></title>
      <link>https://www.redchip.com/webinar/CLCH/86427547349</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/CLCH/86427547349</guid>
      <pubDate>Wed, 26 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Hawkeye Systems (OTC: HWKE)]]></title>
      <link>https://www.redchip.com/webinar/HWKE/81622447096</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/HWKE/81622447096</guid>
      <pubDate>Mon, 31 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Hawkeye Digital is creating a differentiated merchant banking and private equity platform designed to capitalize on the institutionalization of digital assets. Leveraging deep capital markets expertise and an established global network across blockchain and crypto, the Company identifies, acquires, and incubates high-potential businesses while providing investors with diversified exposure to one of the fastest-growing segments of global finance.]]></description>
    </item>
    <item>
      <title><![CDATA[ASP Isotopes]]></title>
      <link>https://www.redchip.com/webinar/ASPI/89403250350</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ASPI/89403250350</guid>
      <pubDate>Tue, 15 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[TransCode Therapeutics (NASDAQ: RNAZ)]]></title>
      <link>https://www.redchip.com/webinar/RNAZ/81817787778</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/RNAZ/81817787778</guid>
      <pubDate>Wed, 16 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[TransCode Therapeutics is a clinical-stage oncology company developing a differentiated portfolio of RNA therapeutics, cancer vaccines, and immuno-oncology therapies designed to address advanced and metastatic cancers. The Company's proprietary nanoparticle delivery platform is engineered to overcome one of the greatest challenges in RNA medicine—efficiently delivering therapeutics directly to tumors beyond the liver—potentially enabling more precise treatment of metastatic disease. TransCode's lead candidate, TTX-MC138, has demonstrated encouraging clinical safety, evidence of tumor-targeted delivery in humans, and promising early efficacy, while advancing into a Phase 2a trial targeting minimal residual disease in colorectal cancer. Supported by technology developed at Harvard Medical School and Massachusetts General Hospital, TransCode has built a diversified oncology pipeline with multiple clinical and preclinical programs, creating several opportunities for value creation through upcoming clinical milestones and potential strategic partnerships.]]></description>
    </item>
    <item>
      <title><![CDATA[Noble Africa]]></title>
      <link>https://www.redchip.com/webinar/NDRA/83554432651</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NDRA/83554432651</guid>
      <pubDate>Thu, 17 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[FibroBiologics (NASDAQ: FBLG)]]></title>
      <link>https://www.redchip.com/webinar/FBLG/85780019692</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/FBLG/85780019692</guid>
      <pubDate>Tue, 22 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[FibroBiologics is a clinical-stage biotechnology company developing allogeneic, fibroblast-based cell therapies to address chronic diseases with large unmet needs. Its novel approach leverages the regenerative, immunomodulatory, and scalable properties of fibroblasts—offering a practical alternative to stem cell therapies. The company’s lead program, CYWC628, targets diabetic foot ulcers and is expected to enter a Phase 1/2 clinical trial in Australia in 2025. Additional candidates include CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis. Backed by over 270+ patents and a growing body of supportive preclinical data, FibroBiologics is advancing a platform with broad therapeutic potential across wound healing, neurodegeneration, and autoimmune conditions. With experienced leadership, strong IP, and near-term clinical catalysts, FibroBiologics offers investors early access to a differentiated, scalable cell therapy platform poised to disrupt multi-billion-dollar markets.]]></description>
    </item>
    <item>
      <title><![CDATA[New Horizon Aircraft]]></title>
      <link>https://www.redchip.com/webinar/HOVR/89061326027</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/HOVR/89061326027</guid>
      <pubDate>Wed, 23 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
  </channel>
</rss>
